EXEL – Exelixis Weekly Chart – this kidney cancer treatment biotech that we’ve had on our watchlist was featured on @InvestorsBusinessDaily today. The last 4 quarters have seen close to 500% growth in sales (quarter over quarter) for the molecule therapy drug developer. That’s a key characteristic in ‘big winning’ stocks.

Exelixis still need more time to consolidate and digest its recent price gains before moving upward, in our opinion.

Here’s an earlier post on TradingRoom

EXEL - Exelixis - Weekly Chart

Copper-futures-analysis